Difference between revisions of "Ferumoxytol (Feraheme)"
m |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.<ref name="insert">[http://www.feraheme.com/ | + | Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.<ref name="insert">[http://www.feraheme.com/pdfs/Feraheme_Full_Prescribing_Information_2015.pdf Ferumoxytol (Feraheme) package insert]</ref><ref>[[Media:Ferumoxytol.pdf | Ferumoxytol (Feraheme) package insert (locally hosted backup)]]</ref><ref>[http://www.amagpharma.com/products/feraheme/ Feraheme manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 7: | Line 7: | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://www.feraheme.com/pdfs/Feraheme_Patient_Information_2015.pdf Ferumoxytol (Feraheme) patient drug information (AMAG Pharmaceuticals)]<ref>[http://www.feraheme.com/pdfs/Feraheme_Patient_Information_2015.pdf Ferumoxytol (Feraheme) patient drug information (AMAG Pharmaceuticals)]</ref> | ||
*[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ferumoxytol-patient-drug-information Ferumoxytol (Feraheme) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *6/30/2009: [http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022180lbl.pdf Initial FDA approval] "for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD)." | ||
==References== | ==References== | ||
Revision as of 04:44, 7 May 2015
General information
Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Ferumoxytol (Feraheme) patient drug information (AMAG Pharmaceuticals)[4]
- Ferumoxytol (Feraheme) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 6/30/2009: Initial FDA approval "for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD)."